Table 3. First-year outcomes in 347 heart transplant patients by donor-recipient gender group.
| Outcome | Group 1a (N = 273) |
Group 2a (N = 40) |
Group 3a (N = 34) |
χ2 or Fb |
Pc |
|---|---|---|---|---|---|
| Deaths | 38 (13.9) | 8 (20.0) | 6 (17.6) | 1.39 | .498 |
| Severe renal dysfunctiond | 93 (34.1) | 19 (47.5) | 6 (17.6) | 8.51 | .014 |
| Steroid-induced diabetes | 26 (9.5) | 4 (10.0) | 3 (8.8) | 0.59 | .744 |
| CAV | 19 (7.0) | 3 (7.5) | 4 (11.8) | 0.07 | .966 |
| Non-skin cancers | 10 (3.7) | 0 | 2 (5.9) | 5.48 | .065 |
| HT length of stay (days)e | 20 ± 18 | 23 ± 14 | 18 ± 9 | 0.73 | .571 |
| Number of days rehospitalizede | 23 ± 25 | 19 ± 19 | 38 ± 38 | 3.76 | .005 |
| Number of treated rejections | 2.9 ± 2.7 | 2.3 ± 2.6 | 4.2 ± 3.7 | 4.11 | .003 |
| Number of IV-treated infections | 1.5 ± 2.3 | 1.6 ± 3.1 | 1.5 ± 1.7 | 0.61 | .652 |
CAV, cardiac allograft vasculopathy; HT, heart transplant; IV, intravenously.
Group 1: same gender donor-recipient; Group 2: female donor-male recipient; Group 3: male donor-female recipient.
Logistic regression (χ2), adjusting for patient age at HT and donor age, was used for dichotomous outcomes, which are expressed as N (%); MANCOVA (F), adjusting for patient age and donor age, was used for continuous outcomes, which are expressed as mean ± standard deviation.
Significance determined at P ≤.005.
Defined as a serum creatinine >2.5 mg/dl, a diagnosis of renal failure, or dialysis, using the definition of the International Society for Heart and Lung Transplantation registry report.2
N = 320: excludes 27 patients who died during the HT admission; Group 1 = 254; Group 2 = 34; Group 3 = 32.